Press Releases

-  UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity -  Phase 2a proof-of-concept study initiated in patients with diabetic macular edema; data expected first half of 2022 -  Cash balance sufficient to fund operations into

UBX1325’s selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema Preclinical data featured in poster presentations at the ARVO 2021 Annual Meeting SOUTH SAN FRANCISCO, Calif. , May 01, 2021 (GLOBE NEWSWIRE) -- UNITY

SOUTH SAN FRANCISCO, Calif. , April 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, will present preclinical data on its lead clinical candidate, UBX1325, at the Association

SOUTH SAN FRANCISCO, Calif. , April 21, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from April 6, 2021 through April 20, 2021 , the Compensation Committee

SOUTH SAN FRANCISCO, Calif. , March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2020

SOUTH SAN FRANCISCO, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has officially joined UNITY as general counsel, and

SOUTH SAN FRANCISCO, Calif. , March 08, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has been appointed general counsel.

SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will participate in the following

SOUTH SAN FRANCISCO, Calif. , Feb. 24, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from February 9, 2021 through February 23, 2021 , the Board of

Study shows that senescent cells accumulate in the eye of patients with diabetic retinopathy, and elimination of these cells in preclinical models ameliorates disease Researchers at UNITY Biotechnology and University of Montreal provide mechanistic evidence supporting potential for vascular